San Diego, CA May 25, 2016 - Objective Capital Partners, LLC is proud to announce that Michael Kim, Vice President, has been selected as a winner of the 2016 M&A Advisor Emerging Leaders Award. The M&A Advisor, renowned globally for its recognition of leading M&A, financing and turnaround professionals, created this event to promote mentorship and professional development amongst the emerging business leaders. Mr. Kim has been chosen for his accomplishments and expertise from a pool of nominees by an independent judging panel of distinguished business leaders.(more…)
San Diego, CA and Bothell, WA - May 17, 2016 – Marina Biotech, Inc. (OTCQB:MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases, announced that the companies have executed a term sheet under which Marina intends to acquire Turing’s intranasal ketamine program. Pending the negotiation of the definitive agreement, Marina is expected to acquire Turing’s intranasal ketamine program for approximately 53 million Marina common shares. Objective Capital Partners, LLC served as an advisor to Marina Biotech in the transaction.(more…)
San Diego, CA- May 10, 2016 - Objective Capital Partners, a leading middle market investment bank focused on transactions for companies with enterprise values up to $500 million, is pleased to announce the equity and debt capitalization of Tavern & Bowl, LLC. (Tavern+Bowl), a leading restaurant and hospitality group. Objective Capital Partners served as the lead financial advisor to Tavern+Bowl providing financial leadership from strategic options assessment, through redesigning the capital structure, financial modeling and supporting the capital acquisition.(more…)
This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.